These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 16713224

  • 1. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment.
    Peters SP, Ferguson G, Deniz Y, Reisner C.
    Respir Med; 2006 Jul; 100(7):1139-51. PubMed ID: 16713224
    [Abstract] [Full Text] [Related]

  • 2. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K.
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G.
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [Abstract] [Full Text] [Related]

  • 4. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma.
    Sullivan SD, Turk F.
    Allergy; 2008 Jun; 63(6):670-84. PubMed ID: 18445184
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic effects of suboptimally controlled asthma.
    Bootman JL, Crown WH, Luskin AT.
    Manag Care Interface; 2004 Jan; 17(1):31-6. PubMed ID: 15035598
    [Abstract] [Full Text] [Related]

  • 6. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
    Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, Fox H, Hedgecock S, Blogg M, Cioppa GD.
    Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
    [Abstract] [Full Text] [Related]

  • 7. Unmet need in inadequately controlled asthma.
    Beasley R.
    Respirology; 2007 Nov; 12 Suppl 3():S18-21; discussion S45-7. PubMed ID: 17956515
    [Abstract] [Full Text] [Related]

  • 8. Immunoglobulin E-mediated airway inflammation is active in most patients with asthma.
    Hayden ML.
    J Am Acad Nurse Pract; 2007 Sep; 19(9):439-49. PubMed ID: 17760568
    [Abstract] [Full Text] [Related]

  • 9. Anti-immunoglobulin E therapy with omalizumab for asthma.
    Hendeles L, Sorkness CA.
    Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
    [Abstract] [Full Text] [Related]

  • 10. Current treatment options for asthma in adults.
    Canham EM, Martin RJ.
    Panminerva Med; 2005 Jun; 47(2):109-22. PubMed ID: 16210996
    [Abstract] [Full Text] [Related]

  • 11. Asthma 2008: targeting immunoglobulin E to achieve disease control.
    Prenner BM.
    J Asthma; 2008 Aug; 45(6):429-36. PubMed ID: 18612893
    [Abstract] [Full Text] [Related]

  • 12. The beneficial effects of Xolair (omalizumab) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available treatment (GINA 2002 step IV)--the Israeli arm of the INNOVATE study.
    Sthoeger ZM, Eliraz A, Asher I, Berkman N, Elbirt D.
    Isr Med Assoc J; 2007 Jun; 9(6):472-5. PubMed ID: 17642399
    [Abstract] [Full Text] [Related]

  • 13. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
    Nowak D.
    Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
    [Abstract] [Full Text] [Related]

  • 14. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations.
    Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G.
    Clin Ther; 2009 May; 31(5):1056-63. PubMed ID: 19539106
    [Abstract] [Full Text] [Related]

  • 15. Add-on omalizumab improves day-to-day symptoms in inadequately controlled severe persistent allergic asthma.
    Humbert M, Berger W, Rapatz G, Turk F.
    Allergy; 2008 May; 63(5):592-6. PubMed ID: 18355388
    [Abstract] [Full Text] [Related]

  • 16. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R.
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [Abstract] [Full Text] [Related]

  • 17. Anti-IgE in severe persistent allergic asthma.
    Fox H.
    Respirology; 2007 Nov; 12 Suppl 3():S22-8; discussion S45-7. PubMed ID: 17956516
    [Abstract] [Full Text] [Related]

  • 18. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma.
    Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, Geba GP, Zeldin RK.
    Clin Pediatr (Phila); 2009 Oct; 48(8):859-65. PubMed ID: 19564449
    [Abstract] [Full Text] [Related]

  • 19. Rationale for the major changes in the pharmacotherapy section of the National Asthma Education and Prevention Program guidelines.
    Kelly HW.
    J Allergy Clin Immunol; 2007 Nov; 120(5):989-94; quiz 995-6. PubMed ID: 17983867
    [Abstract] [Full Text] [Related]

  • 20. Many asthma patients experience persistent symptoms despite appropriate clinical and guideline-based treatment with inhaled corticosteroids.
    Mogil J.
    J Am Acad Nurse Pract; 2007 Sep; 19(9):459-70. PubMed ID: 17760570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.